查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1948965

医用肝臟切片检查钳市场按产品类型、最终用户、应用、材料和操作方式划分，全球预测（2026-2032年）

Medical Liver Biopsy Forceps Market by Product Type, End User, Application, Material, Operation Mode - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年医用肝臟切片检查钳市场价值为 3.7018 亿美元，预计到 2026 年将成长至 3.9912 亿美元，预计到 2032 年将达到 6.2547 亿美元，复合年增长率为 7.78%。

主要市场统计数据
基准年 2025 3.7018亿美元
预计年份：2026年 3.9912亿美元
预测年份：2032年 6.2547亿美元
复合年增长率 (%) 7.78%

本文简要概述了现代医疗环境中影响肝臟切片检查钳选择和采购优先顺序的临床、操作和材料因素。

本执行摘要了目前影响医用肝臟切片检查钳发展趋势的关键因素，重点在于技术进步、临床实践驱动因素、供应链现状以及相关人员的决策标准。它将复杂的证据提炼为可操作的建议，供医疗设备製造商、医院采购部门、门诊诊所和诊断中心等各相关人员参考，帮助领导者在临床疗效、成本控制和法规遵从之间取得平衡，并优先考虑相关行动。

不断发展的临床通讯协定、消毒优先事项、不断增强的供应链韧性以及监管追溯要求正在迅速改变肝臟切片检查钳生态系统。

肝臟切片检查钳的市场格局正受到技术、医疗服务模式和监管要求等多重变革的重塑。微创技术和影像引导切片检查方法的进步，推动了对精准、检体采集率稳定、止血效果可靠的器械的需求。这些操作流程的改进，促使製造商在确保符合灭菌标准的同时，优化器械的人体工学设计和钳尖结构。

评估近期关税变化对肝臟切片检查钳采购、供应和设备可用性供应链成本的累积影响

近期关税和贸易政策的调整对肝臟切片检查钳价值链产生了多方面的影响，包括筹资策略、投入成本和物流。提高某些医疗设备组件和成品的关税措施给下游采购预算带来了压力，这可能会影响一次性器械与可重复使用器械的选择，以及不銹钢与钛等材料的选择。因此，采购团队不仅要评估单位成本，还要评估总到岸成本，后者需要考虑关税、运费、保险和潜在的港口延误。

详细的細項分析揭示了产品类型、最终用户环境、材料选择、分销方式、应用领域和操作模式如何影响采购和临床实施决策。

深入的市场細項分析清楚地揭示了肝臟切片检查钳市场中临床需求与商业性机会的交汇点。根据产品类型，市场可分为可重复使用型和一次性使用型，此区分会影响生命週期成本、消毒负担和环境影响等方面的考量。一次性使用器械简化了感染控制，但会带来持续的耗材成本和废弃物管理方面的挑战；而可重复使用的器械则需要完善的消毒设施、器械追踪流程以及定期的翻新维护。

临床基础设施、法规环境、采购模式和供应链韧性方面的区域差异如何影响全球市场的策略机会？

区域趋势对肝臟切片检查钳的供应商策略、监管重点和临床应用率有显着影响。美洲市场倾向于在感染控制和诉讼风险是主要驱动因素的地区快速采用一次性技术，而在成本压力较大的地区则维持大规模的医院消毒和重复使用基础设施。该地区的采购通常透过与集团采购组织和综合医疗保健系统签订协议，来协商长期服务协议和全面的器械支援服务。

竞争优势取决于设备设计、证据产生、客製化分销策略和强大的售后支援方面的卓越表现，以确保长期的临床应用。

肝臟切片检查钳市场的竞争动态受製造商的设备设计能力、法规应对力、临床证据产生和分销管道等因素的影响。主要企业透过投资优化活检钳的形态、材料科学和製造流程的一致性来脱颖而出，而其他企业则透过拓展服务模式（例如器械翻新服务、消毒培训和综合保固计画）来参与竞争。透过与临床研究中心合作收集数据，可以验证检体品质和操作效率，从而更有力地推动产品被纳入医院药品清单。

为製造商和采购商提供切实可行、影响深远的措施，以提高产品系列和价值链的韧性、临床证据和商业性价值。

产业领导者应优先采取一系列切实可行的倡议，以巩固市场地位并降低营运风险。首先，透过在临床适用的情况下提供一次性使用和可重复使用两种产品系列，并提供透明的生命週期成本和环境影响分析，使产品组合与终端用户需求保持一致，从而为采购决策提供基础。其次，透过提供消毒培训和器械追踪服务来完善产品供应，以减少营运摩擦并提升客户感知价值。

我们透明、多方面的研究途径整合了临床访谈、仪器分析、供应链映射和监管审查，以产生可操作和可重复的研究结果。

本执行摘要的研究结合了对关键相关人员的访谈、临床文献综述、医疗设备规格分析和供应链图谱绘製，以确保研究结果具有可操作性和可复製性。主要资料来源包括对临床医生、采购负责人和医疗设备工程师的结构化访谈，并辅以匿名采购资料和经销商回馈，以了解实际的采购行为和服务期望。研究还回顾了临床结果和手术相关文献，以使器械特性与诊断准确性和手术安全性相关的性能指标相匹配。

综合考虑临床疗效、灭菌实际情况和供应链韧性，提供全面的洞察，以指导器械生命週期中的策略选择。

总之，目前肝臟切片检查钳的现状取决于感染控制优先事项、手术操作性能、操作能力和成本压力之间的平衡。决策者必须权衡一次性器械的便利性和重复使用所带来的长期经济效益，同时也要考虑影响器械耐用性、无菌性和临床医生偏好的材料特性。供应链的脆弱性和关税的波动性使得积极主动的筹资策略和综合采购计画对于维持设备的可用性和财务稳定至关重要。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章 医用肝臟切片检查钳市场（依产品类型划分）

  • 可重复使用的
  • 一次性

第九章 按最终用户分類的医用肝臟切片检查钳市场

  • 诊所
    • 紧急医疗救治
    • 门诊治疗
  • 诊断中心
  • 医院

第十章 按应用分類的医用肝臟切片检查钳市场

  • 诊断
  • 研究
  • 治疗

第十一章 医用肝臟切片检查钳市场（依材料分类）

  • 防锈的
  • 钛

第十二章 依操作方式分類的医用肝臟切片检查钳市场

  • 自动的
  • 手动的

第十三章 各地区医用肝臟切片检查钳市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 医用肝臟切片检查钳市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国医用肝臟切片检查钳市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国医用肝臟切片检查钳市场

第十七章：中国医用肝臟切片检查钳市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Advin Health Care
  • B. Braun Melsungen AG
  • Bansal Surgical Instruments
  • Biomed Technologies
  • Boston Scientific Corporation
  • Contemporary Export Industries
  • Cook Medical LLC
  • Endo-Med Technologies Private Limited
  • Fujifilm Holdings Corporation
  • Golden Nimbus India Private Limited
  • KARL STORZ SE & Co. KG
  • Manish Medi Innovation
  • Medical Equipment India
  • Medtronic plc
  • Olympus Corporation
  • Paul Medical Systems
  • Rajan Surgical Co.
  • Rhythm Surgical
  • Stalwart Meditech Private Limited
  • Vaishanav Surgical Co.
Product Code: MRR-4F7A6D4FB911

The Medical Liver Biopsy Forceps Market was valued at USD 370.18 million in 2025 and is projected to grow to USD 399.12 million in 2026, with a CAGR of 7.78%, reaching USD 625.47 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 370.18 million
Estimated Year [2026] USD 399.12 million
Forecast Year [2032] USD 625.47 million
CAGR (%) 7.78%

A concise synthesis of clinical, operational, and material factors defining device selection and procurement priorities for liver biopsy forceps in contemporary care settings

This executive summary synthesizes current dynamics shaping medical liver biopsy forceps, concentrating on technological progress, clinical practice drivers, supply-chain realities, and stakeholder decision criteria. It distills complex evidence into pragmatic implications for stakeholders across device manufacturing, hospital procurement, outpatient clinics, and diagnostic centers, helping leaders prioritize actions that balance clinical efficacy, cost control, and regulatory compliance.

The device category sits at the intersection of procedural innovation and infection-control imperatives, where choices between reusable and single-use instruments reflect trade-offs in capital expenditure, sterilization logistics, cross-contamination risk, and lifecycle costing. Clinical workflow integration, operator preference, and facility sterilization capacity are central determinants of adoption. Simultaneously, material selection-principally stainless steel or titanium-affects durability, tactile feedback, and compatibility with sterilization modalities. Distribution strategy and sales model choices shape market reach and after-sales support expectations.

Throughout this report, emphasis is placed on rigorous evidence synthesis and operationally relevant recommendations. The aim is to equip decision-makers with a clear understanding of where clinical value intersects with economic sustainability, and where targeted investments in training, procurement practices, and supplier collaboration can yield measurable improvements in patient safety and institutional efficiency.

How evolving clinical protocols, sterilization priorities, supply-chain resilience efforts, and regulatory traceability demands are rapidly reshaping the liver biopsy forceps ecosystem

The landscape for liver biopsy forceps is being reshaped by multiple transformative shifts that span technology, care delivery models, and regulatory expectations. Advances in minimally invasive techniques and imaging-guided biopsy practices are increasing demand for instruments that offer precision, consistent sample yield, and reliable hemostasis. These procedural refinements create pressure for manufacturers to optimize instrument ergonomics and jaw design while maintaining compatibility with sterilization standards.

At the same time, infection prevention imperatives and concerns about prion or viral transmission have strengthened the case for single-use devices in many settings, though reusable forceps retain appeal where sterilization capacity and environmental policies favor instrument reprocessing. Supply-chain resilience has moved to the forefront following global disruptions, incentivizing strategic supplier diversification and a rethinking of inventory models to reduce single points of failure. Digital procurement tools and vendor scorecards are increasingly used to assess supplier risk, delivery performance, and regulatory compliance documentation.

Regulatory scrutiny around device traceability and post-market surveillance has intensified, prompting manufacturers to invest in better labeling, lot tracking, and adverse-event reporting systems. Finally, the convergence of cost containment pressures and quality metrics within health systems is accelerating demand for robust clinical evidence demonstrating comparative procedural outcomes, driving closer collaboration between manufacturers and clinical research centers to generate the data necessary for guideline inclusion and broader clinical adoption.

Assessing the cumulative supply-chain, cost, and procurement impacts of recent tariff changes on liver biopsy forceps procurement, sourcing, and device availability

Recent tariff actions and trade policy adjustments present multifaceted implications for the liver biopsy forceps value chain, influencing sourcing strategies, input costs, and logistics. Tariffs that increase duties on certain medical device components or finished instruments create downstream pressure on procurement budgets, which can in turn affect decisions about single-use versus reusable devices and the choice of materials such as stainless steel or titanium. Procurement teams must therefore evaluate total landed cost rather than unit price alone, accounting for duties, freight, insurance, and potential delays at ports.

In response to tariff-related cost volatility, many manufacturers and buyers are accelerating supplier diversification and nearshoring initiatives to mitigate exposure to tariff-driven price swings. This shift can improve lead-time reliability and reduce customs complexity, but it also requires investment in qualifying new contract manufacturers and ensuring consistent quality standards. Distributors may adjust inventory policies and service-level agreements to include tariff contingency clauses and more dynamic pricing mechanisms.

Regulatory compliance and classification disputes over tariff codes can lead to delays and unexpected costs; therefore, enhanced customs advisory and legal support are now common components of procurement strategies. Clinicians and hospital administrators should anticipate phased impacts: short-term cost pressures may constrain capital spending, whereas medium-term adjustments in sourcing and supply-chain design can restore margin stability and improve resilience. The cumulative effect underscores the need for integrated commercial and supply-chain planning to preserve device availability and clinical continuity under evolving trade regimes.

Granular segmentation reveals how product type, end-user setting, material choice, distribution approach, application, and operation mode drive procurement and clinical adoption decisions

Insightful segmentation analysis clarifies where clinical needs and commercial opportunity intersect within the liver biopsy forceps landscape. Based on Product Type, market is studied across Reusable and Single Use, and this distinction informs lifecycle cost, sterilization burden, and environmental footprint considerations. Single-use devices simplify infection control but raise recurring consumption and waste management questions, whereas reusable instruments demand sterilization infrastructure, instrument-tracking processes, and periodic refurbishment.

Based on End User, market is studied across Clinics, Diagnostic Centers, and Hospitals. The Clinics is further studied across Ambulatory Care and Outpatient Care. The Hospitals is further studied across Community Care and Tertiary Care. These end-user subtleties determine procurement cycles, purchasing authority, and clinical volume profiles: ambulatory and outpatient sites prioritize ease of use and minimal turnaround times, diagnostic centers emphasize sample quality and throughput, while community and tertiary hospitals balance procedure complexity, staff expertise, and central sterile department capabilities.

Based on Application, market is studied across Diagnostic, Research, and Therapeutic, each driving different performance priorities from sample integrity to instrument robustness. Based on Material, market is studied across Stainless Steel and Titanium, where stainless steel is favored for cost-effectiveness and established sterilization compatibility and titanium is selected for corrosion resistance, lighter weight, and specific clinical preferences. Based on Distribution Channel, market is studied across Direct Sales and Distributors, shaping service models and post-sale support expectations. Finally, based on Operation Mode, market is studied across Automatic and Manual, with automated systems offering consistency and manual instruments favored for tactile control in specific procedures. Together, these segmentation lenses allow suppliers and buyers to align product portfolios, sales strategies, and clinical support services to distinct purchasing cohorts and clinical workflows.

How regional differences in clinical infrastructure, regulatory environments, procurement models, and supply-chain resilience shape strategic opportunities across global territories

Regional dynamics critically influence supplier strategies, regulatory priorities, and clinical adoption rates for liver biopsy forceps. Americas markets tend to emphasize rapid adoption of single-use technologies where infection control and litigation risk are prominent drivers, while also maintaining significant hospital infrastructure for sterilization and reuse where cost pressures necessitate it. Procurement in this region often leverages group purchasing organizations and integrated health-system contracting to negotiate extended service agreements and bundled instrument support.

Europe, Middle East & Africa present heterogeneous regulatory environments and reimbursement models that require localized market approaches; Western European health systems may prioritize sustainability and lifecycle costing, encouraging investments in reusable instruments with efficient reprocessing, whereas some EMEA jurisdictions favor single-use adoption to reduce cross-contamination risk. Variability in hospital scale and access to central sterile services in this region necessitates tailored training and sterilization-compatibility documentation.

Asia-Pacific is characterized by rapid infrastructure expansion in tertiary care centers and a growing private healthcare segment, creating demand for both high-performance reusable instruments and premium single-use options. Supply-chain strategies in this region frequently focus on local manufacturing partnerships, cost-competitive material sourcing, and scaling distribution networks to serve urban and regional care centers. Across all regions, regulatory alignment, supply-chain resilience, and evidence demonstrating clinical outcomes remain central to accelerating adoption.

Competitive positioning hinges on device engineering excellence, evidence generation, tailored channel strategies, and robust after-sales support to secure long-term clinical adoption

Competitive dynamics in the liver biopsy forceps segment are influenced by manufacturers' capabilities in device engineering, regulatory affairs, clinical evidence generation, and distribution reach. Leading companies differentiate through investments in jaw geometry optimization, material science, and manufacturing consistency, while others compete by expanding service models such as instrument refurbishment, sterilization training, and integrated warranty programs. Partnerships with clinical research centers support data collection that validates sample quality and procedural efficiency, strengthening purchase cases in hospital formularies.

Channel strategies vary: some firms maintain direct sales teams to service large health systems and provide clinical education, whereas others rely on established distributor networks to extend reach into ambulatory and regional facilities. Pricing models increasingly consider total cost of ownership and offer bundled service contracts to address sterilization, inventory management, and replacement parts. After-sales support, including training, maintenance, and adverse-event responsiveness, is a critical differentiator that influences long-term procurement decisions.

New entrants and niche players often focus on specific materials such as titanium or on operation modes like automated systems to capture specialized clinical segments. Competitive positioning also depends on regulatory readiness and the agility to adapt labeling, traceability, and post-market surveillance processes in jurisdictions with evolving medical device regulations. Overall, market leaders combine product performance with robust commercial and clinical support to secure sustainable adoption.

Practical high-impact actions for manufacturers and purchasers to enhance resilience, clinical evidence, and commercial value across product portfolios and supply chains

Industry leaders should prioritize a set of actionable initiatives to strengthen market position and mitigate operational risk. First, align product portfolios with end-user needs by offering both single-use and reusable options where clinically appropriate, and provide transparent lifecycle costing and environmental impact analyses to inform procurement decisions. Complement product offerings with sterilization training and instrument-tracking services that reduce operational friction for customers and enhance perceived value.

Second, fortify supply-chain resilience through supplier diversification, qualified secondary manufacturing sources, and regional stocking hubs to reduce tariff and logistics exposure. Incorporate tariff contingency planning into commercial agreements and develop flexible pricing frameworks that reflect duty fluctuations. Third, invest in clinical evidence generation-collaborative studies with tertiary centers and diagnostic laboratories that quantify sample quality, complication rates, and procedural efficiency will accelerate guideline recognition and payer acceptance.

Fourth, refine go-to-market strategies by segmenting customers according to application, material preference, and operational capabilities, enabling tailored sales engagement and service packages. Finally, enhance post-market surveillance, lot traceability, and regulatory documentation to meet growing expectations for device transparency and patient safety. These steps together create a defensible commercial position while addressing the operational realities of hospitals, clinics, and diagnostic centers.

A transparent, multi-method research approach integrating clinical interviews, device analyses, supply-chain mapping, and regulatory review to produce actionable and reproducible insights

The research underpinning this executive summary combines primary stakeholder interviews, clinical literature review, device specification analysis, and supply-chain mapping to ensure findings are actionable and reproducible. Primary inputs include structured interviews with clinicians, procurement officers, and device engineers, complemented by anonymized procurement data and distributor feedback to capture real-world purchasing behavior and service expectations. Clinical outcomes and procedural literature were reviewed to align device characteristics with performance metrics relevant to diagnostic yield and procedural safety.

Device material analyses and sterilization compatibility reviews were conducted using manufacturer technical specifications and industry-standard sterilization guides to assess lifecycle and maintenance implications. Supply-chain assessment utilized public customs classifications, shipping patterns, and logistics expert consultation to evaluate tariff exposure and lead-time variability. Quality control and regulatory readiness were evaluated through a review of device labeling practices, traceability systems, and adverse-event reporting frameworks.

Findings were triangulated across data sources to mitigate bias and ensure robustness. Where primary data were limited, conservative interpretations were adopted and flagged for further study. The methodology emphasizes transparency in assumptions and provides a clear audit trail for stakeholders seeking deeper methodological detail or dataset access.

Summative insights that reconcile clinical efficacy, sterilization realities, and supply-chain resilience to guide strategic choices across the device lifecycle

In conclusion, the liver biopsy forceps landscape is defined by a balancing act between infection-control priorities, procedural performance, operational capacity, and cost pressures. Decision-makers must reconcile the trade-offs between single-use convenience and reusable long-term economics while accounting for material attributes that influence durability, sterilization, and clinician preference. Supply-chain fragility and tariff volatility necessitate proactive sourcing strategies and integrated procurement planning to sustain device availability and fiscal stability.

The interplay of segmentation factors-product type, end user nuance, application focus, material choice, distribution channel, and operation mode-creates differentiated opportunity areas for manufacturers who can align engineering innovations with robust clinical evidence and tailored service models. Regionally informed strategies that reflect local regulatory and infrastructure realities will accelerate adoption and reduce implementation friction. Ultimately, organizations that combine clinical partnership, supply-chain resilience, and clear total-cost narratives will be best positioned to deliver patient-safe, efficient, and economically sustainable biopsy solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Medical Liver Biopsy Forceps Market, by Product Type

  • 8.1. Reusable
  • 8.2. Single Use

9. Medical Liver Biopsy Forceps Market, by End User

  • 9.1. Clinics
    • 9.1.1. Ambulatory Care
    • 9.1.2. Outpatient Care
  • 9.2. Diagnostic Centers
  • 9.3. Hospitals

10. Medical Liver Biopsy Forceps Market, by Application

  • 10.1. Diagnostic
  • 10.2. Research
  • 10.3. Therapeutic

11. Medical Liver Biopsy Forceps Market, by Material

  • 11.1. Stainless Steel
  • 11.2. Titanium

12. Medical Liver Biopsy Forceps Market, by Operation Mode

  • 12.1. Automatic
  • 12.2. Manual

13. Medical Liver Biopsy Forceps Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Medical Liver Biopsy Forceps Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Medical Liver Biopsy Forceps Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Medical Liver Biopsy Forceps Market

17. China Medical Liver Biopsy Forceps Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Advin Health Care
  • 18.6. B. Braun Melsungen AG
  • 18.7. Bansal Surgical Instruments
  • 18.8. Biomed Technologies
  • 18.9. Boston Scientific Corporation
  • 18.10. Contemporary Export Industries
  • 18.11. Cook Medical LLC
  • 18.12. Endo-Med Technologies Private Limited
  • 18.13. Fujifilm Holdings Corporation
  • 18.14. Golden Nimbus India Private Limited
  • 18.15. KARL STORZ SE & Co. KG
  • 18.16. Manish Medi Innovation
  • 18.17. Medical Equipment India
  • 18.18. Medtronic plc
  • 18.19. Olympus Corporation
  • 18.20. Paul Medical Systems
  • 18.21. Rajan Surgical Co.
  • 18.22. Rhythm Surgical
  • 18.23. Stalwart Meditech Private Limited
  • 18.24. Vaishanav Surgical Co.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OPERATION MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OUTPATIENT CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OUTPATIENT CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OUTPATIENT CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY TITANIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY TITANIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY TITANIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OPERATION MODE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY AUTOMATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY AUTOMATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY AUTOMATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MANUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MANUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OPERATION MODE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OPERATION MODE, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OPERATION MODE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OPERATION MODE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OPERATION MODE, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OPERATION MODE, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OPERATION MODE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OPERATION MODE, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OPERATION MODE, 2018-2032 (USD MILLION)
  • TABLE 115. GCC MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GCC MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GCC MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 119. GCC MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. GCC MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 121. GCC MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OPERATION MODE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OPERATION MODE, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OPERATION MODE, 2018-2032 (USD MILLION)
  • TABLE 136. G7 MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. G7 MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 140. G7 MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. G7 MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 142. G7 MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OPERATION MODE, 2018-2032 (USD MILLION)
  • TABLE 143. NATO MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NATO MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 147. NATO MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. NATO MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 149. NATO MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OPERATION MODE, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OPERATION MODE, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA MEDICAL LIVER BIOPSY FORCEPS MARKET SIZE, BY OPERATION MODE, 2018-2032 (USD MILLION)